.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Cipla
Fish and Richardson
Harvard Business School
Farmers Insurance
Merck
Queensland Health
Healthtrust
Chinese Patent Office
Julphar

Generated: September 26, 2017

DrugPatentWatch Database Preview

Cabazitaxel - Generic Drug Details

« Back to Dashboard

What are the generic sources for cabazitaxel and what is the scope of cabazitaxel patent protection?

Cabazitaxel
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cabazitaxel has one hundred and ninety-six patent family members in fifty-eight countries.

There are thirteen drug master file entries for cabazitaxel. One supplier is listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: cabazitaxel

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list13
Suppliers / Packagers: see list1
Bulk Api Vendors: see list31
Clinical Trials: see list94
Patent Applications: see list63
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:cabazitaxel at DailyMed

Tentative approvals for CABAZITAXEL

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe20MG/ML(60MG/3ML)INJECTABLE;INJECTION
► Subscribe► Subscribe60MG/6MLINJECTABLE;INJECTION
► Subscribe► Subscribe40MG/4MLINJECTABLE;INJECTION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: cabazitaxel

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: cabazitaxel

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,889,043 Taxoids, preparation thereof and pharmaceutical Compositions containing same► Subscribe
6,387,946 Methods for treating pathological conditions of abnormal cell proliferation► Subscribe
6,593,482 Methods for preparing new taxoids and pharmaceutical compositions containing them► Subscribe
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein► Subscribe
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
6,187,916 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
6,232,477 Methods of preparing new taxoids and pharmaceutical compositions containing them► Subscribe
6,040,466 Taxoids, their preparation and pharmaceutical compositions containing them► Subscribe
6,331,635 Taxoids, their preparation and pharmaceutical compositions containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cabazitaxel

Country Document Number Estimated Expiration
Canada2154071► Subscribe
MontenegroP11708► Subscribe
Japan2941951► Subscribe
Dominican RepublicP2012000118► Subscribe
Austria188471► Subscribe
Australia711227► Subscribe
JapanH08506339► Subscribe
Spain2140075► Subscribe
Morocco23823► Subscribe
Georgia, Republic ofP20002188► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CABAZITAXEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013000050Germany► SubscribePRODUCT NAME: ACETON-SOLVAT VON CABAZITAXEL; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
C0037France► SubscribePRODUCT NAME: CABAZITAXEL SOUS FORME ACETONATE (OU SOLVAT ACETONIQUE DU CABAZITAXEL); REGISTRATION NO/DATE: EU/1/11/676/001 20110322
1 5019-2013Slovakia► SubscribeFIRST REGISTRATION NO/DATE: EU/1/11/676/001 20110317
00595Netherlands► SubscribePRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986/01Switzerland► SubscribePRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011
90025-3Sweden► SubscribePRODUCT NAME: CABAZITAXEL ACETONSOLVAT; REG. NO/DATE: EU/1/11/676/001 20110317
/2013Austria► SubscribePRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013 00025Denmark► Subscribe
0130017 00077Estonia► SubscribePRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
13/021Ireland► SubscribePRODUCT NAME: CABAZITAXEL ACETONE SOLVATE; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
McKinsey
Federal Trade Commission
QuintilesIMS
Chubb
Deloitte
US Army
Argus Health
Cantor Fitzgerald
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot